Jan 1, 1975

Differential antianginal responsiveness to acebutolol

European Journal of Clinical Pharmacology
P Biron, G Tremblay

Abstract

Six unselected males suffering from documented coronary insufficiency and grade II to III angina were submitted to graded multistage treadmill exercise test on 3 separate occasions, 3.5 hours after ingestion of either 0, 200 or 400 mg of acebutolol, a new cardioselective beta-blocker. Control measures included the random allocation to 6 balanced sequences of administration, the rigid standardisation of double-blind experimental conditions and measurements, and two types of variance analysis (latin-square and split-plot). Performance was evaluated by measuring time elapsed before occurrence of anginal pain and ECG changes, peak heart rate, peak double product (heart rate x systolic pressure), and peak oxygen consumption. The mean values for all 5 criteria showed improvement with the 200 mg dose of acebutolol, and even more so with 400 mg, but this overall effect resulted mainly from the excellent response of 3 of the patients. When patients were grouped into 2 categories of responders and non-responders, a significant Dose x Category interaction was found for all criteria. Furthermore, maximal response under acebutolol was negatively correlated with values under placebo (0 mg); this correlation reached significance for peak hear...Continue Reading

  • References
  • Citations5

References

  • We're still populating references for this paper, please check back later.

Mentioned in this Paper

Muscle Rigidity
Rhotral
Diastolic Blood Pressure
G2 Stage (Tumor Staging)
Cardiopulmonary Exercise Test
Coronary Artery Insufficiency
Exercise Stress Test
Angina Pectoris
Ingestion
Clinical Trials

About this Paper

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.